Mineralys Therapeutics, Inc. (MLYS) insider trading

By person

15 insiders · 0 transactions

21.1×

Jon Congleton holds 21.1 times base salary in stock. $13.46M of shares against $636.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Jon Congleton last reported holding, valued at $25.46, the price Common Stock was last bought or sold at on the open market here, on 30 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Brian Taylor Slingsby

Director

—

15,715,756

17.78%

$400.16M

−5.1%

Ra Capital Management, L.p. entity

Director

—

5,825,521

6.59%

$148.33M

+95.6%

Samsara BioCapital GP, LLC entity

10% owner

—

5,674,916

6.42%

$144.50M

+11.8%

Srinivas Akkaraju

Director

—

594,435

0.6724%

$15.14M

—

Jon Congleton

Chief Executive Officer

—

528,621

0.5979%

$13.46M

−41.0%

James J. Ferguson III

Chief Medical Officer

—

102,400

0.1158%

$2.61M

—

David Malcom Rodman

Chief Medical Officer

—

51,384

0.0581%

$1.31M

−63.1%

Adam Scott Levy

CFO and Secretary

—

48,538

0.0549%

$1.24M

−67.6%

Eric Warren

Chief Commercial Officer

—

38,400

0.0434%

$977.75K

0.0%

Lonnel Coats

Director

—

12,400

0.0140%

$315.73K

—

Kristine Peterson

Director

—

12,400

0.0140%

$315.73K

—

Daphne Karydas

Director

—

6,200

0.0070%

$157.87K

—

Glenn Sblendorio

Director

—

6,200

0.0070%

$157.87K

—

Alexander M Gold

Director

—

6,200

0.0070%

$157.87K

—

Derek DiRocco

Director

—

6,200

0.0070%

$157.87K

—

Mineralys Therapeutics, Inc.

What the insiders did No buying or selling

By person